HIGHBuilt-inProduct / Revenue mix
52%
advanced imaging (MRI/CT/PET)
“10-K Item 1: 'advanced imaging accounted for 52% of our consolidated revenue and 63% of our system-wide revenue'”
LMRI · Concentration risk · 10-K extracted
Lumexa Imaging Holdings (LMRI) concentration risks
Updated
The most significant concentration Lumexa Imaging Holdings discloses is advanced imaging (MRI/CT/PET) at 52%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Lumexa Imaging Holdings’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Lumexa Imaging Holdings' disclosed concentration is a single, high-share structural exposure: advanced imaging modalities — MRI, CT and PET — accounted for 52% of consolidated revenue and 63% of system-wide revenue. Because this is a structural rather than counterparty-driven exposure, the risk is embedded in the business model itself: the company's fortunes are closely tied to reimbursement rates, technology costs, and demand trends specific to advanced imaging rather than to the loss of any single customer or supplier relationship. With no customer, geographic, or supplier concentration separately disclosed at this size, advanced imaging is effectively the whole story for concentration risk here. The gap between the consolidated 52% figure and the higher 63% system-wide figure suggests advanced imaging is an even larger share of the managed-system network than of Lumexa's own consolidated books, meaning the company's economics are more exposed to this modality mix than the headline revenue split alone implies.
For the engine’s reasoning on LMRI’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| AVNS | Avanos Medical, Inc. | 2 | 0 | 1 | 3 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| LMRI● | Lumexa Imaging Holdings, Inc. | 1 | 0 | 0 | 1 |
| AHCO | AdaptHealth Corp. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.